TY - JOUR
T1 - Imaging of prostate cancer with positron emission tomography
AU - Zimmerman, Michael E.
AU - Meyer, Alexa R.
AU - Rowe, Steven P.
AU - Gorin, Michael A.
N1 - Publisher Copyright:
© 2019, Millennium Medical Publishing, Inc.. All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Prostate cancer is most commonly imaged through a combination of magnetic resonance imaging, x-ray computed tomography, and99mTc-methylene diphosphonate bone scan. Hese conventional imaging modalities, however, suffer from limited sensitivity and specificity for the detection of disease. This can lead to disease understaging and the improper selection of treatment. To address this problem, a variety of novel radiotracers for positron emission tomography (PET) imaging have been developed. This includes agents that accumulate on the basis of alterations in cellular metabolism (eg,11C-choline and 18F-FACBC) as well as those that bind to specific proteins (eg,68Ga-PSMA-11,18F-DCFPyL, 68Ga- RM2, and18F-DHT). In this review, we examine the performance characteristics of these new PET radiotracers for imaging prostate cancer and discuss ways in which PET imaging can offer more precise clinical information to patients and providers.
AB - Prostate cancer is most commonly imaged through a combination of magnetic resonance imaging, x-ray computed tomography, and99mTc-methylene diphosphonate bone scan. Hese conventional imaging modalities, however, suffer from limited sensitivity and specificity for the detection of disease. This can lead to disease understaging and the improper selection of treatment. To address this problem, a variety of novel radiotracers for positron emission tomography (PET) imaging have been developed. This includes agents that accumulate on the basis of alterations in cellular metabolism (eg,11C-choline and 18F-FACBC) as well as those that bind to specific proteins (eg,68Ga-PSMA-11,18F-DCFPyL, 68Ga- RM2, and18F-DHT). In this review, we examine the performance characteristics of these new PET radiotracers for imaging prostate cancer and discuss ways in which PET imaging can offer more precise clinical information to patients and providers.
KW - Cancer diagnostics
KW - PET
KW - Positron emission tomography
KW - Prostate cancer imaging
KW - Radiotracers
UR - http://www.scopus.com/inward/record.url?scp=85071359049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071359049&partnerID=8YFLogxK
M3 - Article
C2 - 31449514
AN - SCOPUS:85071359049
SN - 1543-0790
VL - 17
SP - 455
EP - 463
JO - Clinical Advances in Hematology and Oncology
JF - Clinical Advances in Hematology and Oncology
IS - 8
ER -